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T-cell immunity in the liver is tightly regulated to prevent chronic liver inflammation in
response to antigens and toxins derived from food and intestinal bacterial flora. Since
the main sites of T cell activation in response to foreign components entering solid
tissues are the draining lymph nodes (LN), we aimed to study whether Antigen-Presenting
Cell (APC) subsets in human liver lymph-draining LN show features that may contribute
to the immunologically tolerant liver environment. Healthy liver LN, iliac LN, spleen
and liver perfusates were obtained from multi-organ donors, while diseased liver
LN were collected from explanted patient livers. Inguinal LN were obtained from
kidney transplant recipients. Mononuclear cells were isolated from fresh tissues, and
immunophenotypic and functional characteristics of APC subsets were studied using
flowcytometry and in ex vivo cultures. Healthy liver-draining LN contained significantly
lower relative numbers of CD1c+ conventional dendritic cells (cDC2), plasmacytoid DC
(PDC), and CD14+CD163+DC-SIGN+ macrophages (MF) compared to inguinal LN.
Compared to spleen, both types of LN contained low relative numbers of CD141hi
cDC1. Both cDC subsets in liver LN showed a more activated/mature immunophenotype
than those in inguinal LN, iliacal LN, spleen and liver tissue. Despite their more
mature status, cDC2 isolated from hepatic LN displayed similar cytokine production
capacity (IL-10, IL-12, and IL-6) and allogeneic T cell stimulatory capacity as their
counterparts from spleen. Liver LN from patients with inflammatory liver diseases showed
a further reduction of cDC1, but had increased relative numbers of PDC and MF.
In steady state conditions human liver LN contain relatively low numbers of cDC2,
PDC, and macrophages, and relative numbers of cDC1 in liver LN decline during liver
inflammation. The paucity of cDC in liver LN may contribute to immune tolerance in
the liver environment.
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INTRODUCTION
The liver is continuously exposed to food components and bacterial products that enter the liver
from the gastrointestinal tract via the portal vein. To prevent continuous liver inflammation
in response to these gut-derived components, local immune responses in the liver are tightly
regulated. Therefore, the liver environment favors induction of peripheral immune tolerance rather
than immunity (1).
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It has been hypothesized that dendritic cells (DC) are
key players in maintaining the fine balance between T-
cell responsiveness and unresponsiveness in the liver (2).
Conventional DC (cDC) are the most highly specialized antigen-
presenting cells (APC) and they play a critical role in the
initiation and direction of T-cell responses (3, 4). Immature cDC
are located throughout most body tissues and are specialized
in the uptake and processing of antigens. Under steady state
conditions there is a continuous migration of antigen-loaden
cDC from non-lymphoid tissues through the lymphatics toward
the draining lymph nodes (LN), where they present antigens
that they acquired in their tissue of origin to T cells, and
this process is accelerated in response to inflammatory signals.
During migration to LN, cDC complete their maturation and
acquire potent T cell stimulatory capacity by upregulation of
MHC and co-stimulatory molecules (5). In addition to migratory
cDC, LN contain resident cDC which emerge from circulating
precursors and spend their entire lives within LN, where they
acquire antigens from non-lymphoid tissue that in soluble form
via lymphatic drainage enter LN, and present them to T cells (6).
Human cDC can be subdivided into two distinct ontogeneic
lineages: type 1 cDC (cDC1) which express high levels of CD141
(BDCA3) and the necrotic cell receptor CLEC9a, and type 2 cDC
(cDC2) that express CD1c (BDCA1) (7–9). Both cDC subsets
are potent stimulators of CD4+ T-cell responses (10), but differ
in stimulatory capacity of CD8+ T cells. cDC1 have a superior
ability to cross-present antigens from necrotic cells to CD8+ T
cells compared to cCD2 (11–14). The cross-presenting capacity
of cDC2 is still unclear, although recent data suggest that they
can cross-present soluble antigens (15).
Next to cDC, plasmacytoid DC (PDC) are a separate DC
lineage. PDC are unique in rapidly producing massive amounts
of type I interferon upon recognition of viral nucleotides or
self-DNA-protein complexes by their Toll-Like receptors (TLR).
Although PDC have weaker antigen presenting capacity than
cDC, they can mature upon stimulation and prime CD4+
and CD8+ T cell responses (9, 16). On the other hand they
can contribute to immunological tolerance by their capacity to
generate CD4+ and CD8+ regulatory T cells (Treg) from naïve
CD4+ or CD8+ T cells, respectively (17, 18).
Considerable efforts have been done to study whether DC in
liver tissue possess unique characteristics that may contribute
to immunological tolerance in the liver, but contradictory
conclusions have been reached. On the one hand, mouse liver
MDC were reported to have an immature phenotype and to be
functionally compromised (19–22). On the other hand, however,
other studies found no functional differences between distinct
DC subsets in mouse liver and spleen, but reported differences
in DC subset composition between both tissues (23, 24). In
comparison to blood, human liver was shown to contain more
cDC1 (25). In addition, human liver cDC2 produce higher
amounts of the anti-inflammatory cytokine IL-10 compared to
blood or skin MDC, although also being able to produce pro-
inflammatory cytokines upon TLR-stimulation (26–28).
T cell activation by DCs is generally not initiated in
parenchymal tissue, but in specific secondary lymphoid organs
like the spleen or tissue-draining LN. In humans, major liver
lymph vessels leave the liver at the hilus, and liver-derived lymph
drains to LN situated at the hilus and along the hepatic artery
and portal vein (29). Experimental animal studies have shown
that cDC that migrate from the liver are trapped in liver-draining
LN (30–32), and that T-cell activation to antigens delivered into
the liver mainly occurs in these LN (32, 33). In humans, T cells
specific for HBV antigens have been found to be enriched in
liver-draining LN and not in the liver itself (34).
Despite the probable importance of hepatic LN in the
regulation of T cell responses to antigens in the liver, very little
is known about the composition and functions of APC in human
liver lymph-draining LN. We therefore asked whether APC in
liver LN differ from their counterparts in LN located at sites
of the body where predominantly immunogenic responses are
required, such as inguinal LN to which lymph from the legs is
drained and which should be able to react to external pathogens
upon disturbances of the skin barrier. The aim of this study
was therefore to compare subset composition, phenotype and
functions of themain known humanAPC subsets in human liver-
draining LN with their counterparts in skin and muscle-draining
inguinal LN. In addition, we compared APC subsets in liver LN
with those in another secondary lymphoid tissue, i.e., spleen,
and with those in human liver tissue, which contains cDC that
migrate to liver LN.
TISSUES, MATERIALS, AND METHODS
Collection of Lymph Nodes, Spleen, and
Liver Perfusate
Spleen tissues were obtained from multi-organ donors during
organ donation procedures for the purpose of donor HLA-
typing, and residual tissue was used for research. Iliac LN
were collected for research purposes from 6 multi-organ donors
during organ donation procedures. Hepatic LN were resected
along the hepatic artery and portal vein in the porta hepatis
from donor livers and diseased patient explant livers during
liver transplantation procedures. Liver leukocytes were collected
during routine perfusion of liver grafts immediately before
transplantation, as we described previously (27). Inguinal LN
were obtained from kidney transplant recipients during kidney
transplantation procedures, and are considered as skin/muscle
draining LN. The Ethics Committee of the Erasmus MC
approved collection of the tissues for research purposes, and
informed consent of each patient was obtained.
Reagents
The following mAbs and reagents were used: IgG1-FITC, IgG1-
PerCP-Cy5.5, IgG2a-APC, IgG1-PB, CD14-PE, CD14-PerCP,
CD45-HorizonV500, streptavidin-PerCP, anti-IFNγ-FITC,
7AAD and Lineage cocktail-FITC (CD3, 16,19, 20,14, 56)
from BD Biosciences, Erembodegem, Belgium; CD80-
FITC from Beckman Coulter, Woerden, the Netherlands;
anti-BDCA1-PE, anti-BDCA2-FITC, anti-BDCA2-biotin,
anti-BDCA4-PE, anti-BDCA3-APC, anti-Clec9a-VioBlue,
CD19 microbeads and anti-PE-microbeads from Miltenyi
Biotec, Bergisch Gladbach, Germany; CD1a-PB, CD209 (DC-
SIGN)-PECy7, CD206-eFluor450, CD40-APC and CD274
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(PDL1)-PECy7 from eBioscience, Vienna, Austria; CD86-APC,
CD86-PB, CD163-PerCP-Cy5.5, CD40-PerCP-Cy5.5, HLA
DR-APC-Cy7 and CD209 (DC-SIGN)-APC from Biolegend,
London, United Kingdom. PMA, ionomycin and brefeldin
A are from Sigma-Aldrich, St Louis, MO. The fix&perm
cell permeabilization kit was obtained from An der Grub,
Vienna, Austria.
Isolation of Mononuclear Cells (MNC)
Lymph nodes and spleen tissues were cut into small pieces and
treated with 500µg/ml collagenase type IV and 200µg/ml
DNAse I (both from Sigma Aldrich, Zwijndrecht, the
Netherlands) at 37◦C. After 20min the collagenase reaction
was stopped by adding fetal bovine serum and the tissue pieces
were passed over a nylon mesh filter (100µm pore diameter)
to obtain single cell suspensions. To determine possible effects
of collagenase on surface molecule expression, in preliminary
experiments LN and spleen tissues were divided into two parts,
and one part was treated with collagenase and the other part
not. We observed that yields of MDC subsets were considerably
increased upon isolations with collagenase, and therefore all
data presented in the paper are derived from cells isolated by
collagenase treatment, except data on liver cells because these
were obtained using single cells collected from liver perfusates.
MNC were obtained from single cell suspensions of tissue by
Ficoll Paque (GE Healthcare Biosciences AB, Uppsala, Sweden)
density gradient centrifugation. Cell yield and viability was
determined by counting with trypan blue.
Flowcytometry
Flowcytometric analysis was used to immunophenotype splenic,
lymph node-, and liver APC. MNC were labeled with different
antibody combinations. Appropriate isotype matched control
antibodies were used to determine gates. APC subsets were
determined within a MNC gate after exclusion of CD45−
non-hematopoietic cells and 7AAD+ dead cells. cDC subsets
were distinguished on basis of CD11c, CD1c, and CD141
expression. PDC were defined as BDCA2+BDCA4+ cells, and
monocytes/macrophages as CD14+. At least 500,000 events were
acquired using a FACSCanto II flowcytometer and analyzed using
FACSDiva 6.1 software (BD Biosciences) And Flowjo software
(version 10.2, BD Biosciences).
Purification of cDC2 and PDC
cDC2 were enriched from hepatic LN and spleen MNC
by incubation with CD19, CD3, and CD15 microbeads and
depletion of B and T cells and granulocytes by separation over
a Large Depletion column using a MidiMACS separation device
(Miltenyi Biotec, Bergisch Gladbach, Germany). Subsequently,
the non-adherent cells were labeled with CD1c-PE, CD14-PerCP
and CD20-Pacific Blue antibodies, and cDC2 were isolated by
flowcytometric cell sorting by first excluding CD14+ and CD20+
cells, and subsequent selection of CD1c+ cells. Purity of the
isolated cDC2 as determined by flowcytometry was typically
>95%. To isolate PDC, LN MNC were labeled with anti-
PE-conjugated anti-BDCA-4 antibody and anti-PE microbeads
(Miltenyi Biotec) and purified by two round of separation over
MS columns.
Cytokine Production and T-Cell Stimulatory
Capacity of DC
Purified cDC2 from hepatic LN and spleen from the same
donors were cultured at a concentration of 2 × 104 cells/200
ul in round bottom 96-well culture plates in RPMI1640
supplemented with 10% FCS (Hyclone, Logan, UT, USA),
penicillin (100 U/ml), streptomycin (100 U/ml) and GM-
CSF (500 U/ml; Leucomax, Novartis Pharma, Arnhem, the
Netherlands) and stimulated with either 20µg/ml synthetic
double-stranded RNA (polyriboinosinic-polyribocytidylic acid;
poly I:C; Sigma-Aldrich, St. Louis, MO) and 1,000 U/ml IFN-
γ or CD40L-transfected J558 plasmacytoma cells (2 × 104
cells/well) and 1,000 U/ml IFN-γ for 24 h and 37◦C. After 24 h,
supernatants were harvested and levels of IL-12, IL-6, and IL-
10 were determined by standard enzyme-linked immunosorbent
assay (ELISA) according to the manufacturer’s instructions
(eBioscience, Vienna, Austria).
The T cell stimulatory capacity of cDC2 or PDC was assessed
by co-culturing purifiedMDC or PDC at different concentrations
(10, 5, 2.5, 1.25 × 103 cells/200 ul) in round bottom 96-
well culture plates in RPMI1640 supplemented with 10% FCS,
penicillin and streptomycin with 1.5× 105 CD3+ T cells isolated
by magnetic selection using the pan T-cell isolation kit (Miltenyi
Biotec) from blood of a healthy volunteer. In all experiments
T cells from the same individual were used. After 5 days, T
cell proliferation was assessed by measuring the incorporation
of [3H]-thymidine (Radiochemical Center, Amersham, Little
Chalfont, UK). 0.5 µCi was added per well and cultures were
harvested 18 h later.
To determine their capacity of induce T-helper 1 responses,
1 × 105 CD45RA+CD45RO−CD3+ naïve T cells obtained by
flowcytometric cell sorting from blood of a healthy volunteer,
were co-cultured with 1 × 104 cDC2 isolated from hepatic LN
or spleen. After 7 days T cells were re-stimulated with PMA
(40 ng/ml) and ionomycin (1 ug/ml) for 6 h. During the last
5 h of restimulation brefeldin A (5 ug/ml) was added to inhibit
protein transport processes. Intracellular IFN-γ expression was
determined by using the Fix&perm cell permeabilization kit
according to the manufacturer’s instructions.
Statistical Analysis
The Mann-Whitney U-test was used to test differences between
tissues from different patients, and theWilcoxon signed rank test
was used for analysis of differences between paired tissues of the
same donors. A p < 0.05 was considered significant. GraphPad
Prism 5 software was used to perform the statistical tests.
RESULTS
Characterization of Conventional Dendritic
Cell Subsets in Lymphoid Organs and Liver
To characterize DC subsets in the different tissues, MNC
were isolated from freshly resected hepatic LN, inguinal LN,
spleen, and liver graft perfusates, and analyzed for expression
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of CD45, CD11c, CD1c, CD141, and lineage markers (CD3,
CD14, CD16, CD19, CD20, and CD56). Since leukocytes in
liver graft perfusates accurately represent leukocytes present
in liver tissue (27, 28, 35–37) we will refer to liver perfusate
DC as liver DC. First, we analyzed CD11c expression on
CD45+Lineage−CD1c+ and CD45+Lineage−CD141+ cells. We
observed that lineage−CD1c+ cells express high levels of CD11c,
while part of lin−CD141hi cells were CD11cdim in the different
tissues (Figure 1A). In accordance with previous publications on
cDC subsets in human tissues (9, 14), we concluded that CD141hi
cDC1 have variable CD11c expression. Therefore defined cDC1
as lin−CD141hi cells and cDC2 as lin−CD11c+CD1c+ cells.
Lin−CD141hi cells from liver perfusate also expressed Clec9A,
identifying them as bona fide cDC1 (13, 14). However, Clec9A
expression was reduced or absent on cDC1 in lymphoid tissues
(Figure 1B). This appeared to be due to the collagenase digestion
used to isolate single cells from lymphoid tissues, which was
not required for liver perfusate. Incubation of liver-derived
leukocytes with collagenase resulted in loss of Clec9A expression
on liver-derived cDC1, while isolation of single cells from LN
without collagenase digestion resulted in cDC1 with clear Clec9A
expression (Figure 1B). In none of the tissues cDC1 expressed
CD1a, CD206, or DC-SIGN (data not shown), indicating that
both types of LN, as well as spleen and liver, contain a
homogeneous population of cDC1. In contrast, in all examined
tissues 10–20% of cDC2 expressed CD1a and a small proportion
expressed CD206 (data not shown), suggesting that a minority of
cDC1 may represent migratory DC (38).
Liver LN Contain Relatively Low Numbers
of cDC2
To compare relative numbers of cDC subsets in the different
tissues, we quantified proportions of lineage−CD141bright cDC1
FIGURE 1 | Characterization of cDC subsets in hepatic and inguinal lymph nodes, spleen, and liver. (A) Vital (7-AAD−)CD45+Lineage−CD1c+ and
CD45+Lineage−CD141+cells were gated in MNC isolated from hepatic and inguinal lymph nodes, spleen and liver perfusate, and analyzed for CD11c expression.
(B) Vital (7-AAD−)CD45+Lineage−CD141bright cells were analyzed for Clec9A expression. Cells isolated from lymphoid tissues showed low Clec9A expression, while
their counterparts in liver perfusate were Clec9A+. When liver perfusate cells were incubated with collagenase, Clec9A expression was lost. When leukocytes were
isolated from inguinal LN without collagenase digestion, Clec9A was expressed on cDC2. iLN, inguinal LN.
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and lineage−CD11c+CD1c+ cDC2 within CD45+ cells. Of all
tissues, spleen contained the highest proportions of both cDC
subsets (Figure 2A). Interestingly, hepatic LN contained 6 times
lower proportions of cDC1 compared to inguinal LN (0.053% vs.
0.31%; p = 0.0006), while both types of LN contained small but
similar proportions of cDC2. These data demonstrate a selective
reduction of the relative numbers of the cDC2 subset in human
liver LN.
Both cDC Subsets in Liver LN Are Highly
Activated
To compare the maturation status of both cDC subsets in
the different tissues, we analyzed their expression of HLA-
DR, the co-stimulatory molecules CD40 and CD86, and the
co-inhibitory molecule PDL-1. Because we had no more
than 8 fluorochrome channels available on our FACS, we
omitted CD11c from our gating strategy, and defined cDC2
cells for this analysis as lineage−CD1c+. Nevertheless, all
cDC2 identified by this gating strategy were HLA-DR+, like
cDC1 (Figures 2B,C). Expression levels of HLA-DR on both
cDC subsets was higher in liver LN compared to spleen
and liver (Figures 2B–D). Even more interestingly, in hepatic
LN both cDC subsets expressed significantly higher levels
of CD40, CD86 and PDL-1 compared to their counterparts
in inguinal LN, spleen and liver, indicating that both cDC
subsets in hepatic LN are in a more activated/mature status.
To exclude that the observed differences in maturation status
were confounded by possible differences between multi-organ
donors (from which hepatic LN, spleens and liver perfusates
were collected) and kidney transplant recipients (from which
inguinal LN were obtained), paired comparisons of expression
of HLA-DR, CD40, CD80, CD83, CD86, and PDL-1 on
cDC2 in hepatic and iliac LN derived from the same multi-
organ donors were performed. The data derived from these
measurements confirm that cDC2 in hepatic LN have a
more mature/activated immunophenotype compared to their
counterparts in non-liver-draining LN (Figure 2E). Finally, we
analyzed HLA-DR, CD40, and CD86 expression on cDC2 in
2 additional sets of tissues using antibody panels in which
we replaced PD-L1 antibody by CD11c antibody, allowing for
gating of cDC2 as lineage−CD11c+CD1c+ cells. This gating
strategy yielded similar results for expression levels of HLA-
DR and co-stimulatory molecules as the gating strategy without
CD11c (Figure 2F).
FIGURE 2 | (Continued).
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FIGURE 2 | Relative cDC subset numbers and their maturation status in hepatic and inguinal lymph nodes, spleen and liver. (A) The proportions of
lineage−CD141brightcDC1 and lineage−CD11c+CD1c+ cDC1were determined within CD45+ MNC. Dead cells were excluded from the analysis by excluding
7AAD+ cells. Dots represent individual tissues, and lines indicate mean values. Hepatic LN, spleen tissues, and liver perfusates were obtained from the same
multi-organ donors, while inguinal LN were collected from kidney transplant recipients. (B) Histograms showing expression of HLA DR, CD40, CD86, and PDL-1 on
lineage−CD141brightcDC1 from hepatic lymph nodes, inguinal lymph nodes, spleen, and liver. Light gray histograms are isotype control stains. (C) Histograms
showing expression of HLA DR, CD40, CD86, and PDL-1 on lineage−CD1c+cDC2 in hepatic lymph nodes, inguinal lymph nodes, spleen, and liver. Light gray
histograms are isotype control stains. (D) Summary of expression levels (MFI) of HLA DR, CD40, CD86, and PDL-1 on lineage−CD141brightcDC1 and
lineage−CD1c+cDC2 in liver LN (n = 6) and inguinal lymph nodes (n = 7), spleen (n = 6) and liver (n = 6). Data are depicted as means ± SEM. (E) Expression levels
of HLA-DR, CD86, CD80, CD40, CD83, and PDL-1 was determined on cDC2 in MNC isolated from paired liver LN and iliac LN from the same multi-organ donors (n
= 6). (F) Comparison of the expression levels of HLA-DR, CD40, and CD86 on cDC2 in tissues of 2 different liver transplant donors gated as lineage−CD11c+CD1c+
(CD11c) cells or as lineage−CD1c+ without inclusion of CD11c in the gating strategy (wt).
cDC2 in Hepatic Lymph Nodes Are
Functionally Similar to Those in Spleen
We compared the functional properties of the most prominent
cDC-subset present in hepatic LN, i.e., the cDC2, with those
of its counterpart in spleen. cDC2 were purified from hepatic
LN and spleen MNC obtained from the same donors and we
analyzed their cytokine production upon ex vivo stimulation
with CD40L plus IFN-γ or TLR3-agonist poly I:C plus
IFN-γ. Since synergistic stimulation via TLR or CD40 with
IFN-γ is required to induce maximal IL-12 production by
human cDC2 (39), we added IFN-γ in all conditions. The
cells secreted the pro-inflammatory cytokines IL-12 and IL-
6 as well as the immune-regulatory cytokine IL-10 without
apparent differences between those derived from hepatic LN and
spleen (Figure 3A).
In addition, we compared their T-cell stimulatory capacity.
Despite their more mature immunophenotype, cDC2 from
liver LN demonstrated a comparable capacity to stimulate
proliferation of allogeneic T-cells as their counterparts isolated
from spleen (Figure 3B). Moreover, cDC2 from hepatic LN and
spleen induced IFN-γ production in naïve allogeneic T-cells
(Figure 3C) to a comparable extent.
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FIGURE 3 | cDC2 isolated from hepatic lymph nodes and spleen are functionally similar. (A) cDC2 were purified from hepatic LN and spleen MNC from the same
donors by immunomagnetic depletion of granulocytes, T cells and B cells followed by flowcytometric sorting of CD1c+CD14−CD20− cells as described in the
Methods section, and 2 × 104 cells/200 µl were stimulated with either CD40L-transfected plasmacytoma cells (2 × 104 J558 cells) and 1,000 U/ml IFN-γ, or with
20µg/ml poly IC and 1,000 U/ml IFN-γ for 24 h at 37◦C. After 24 h, supernatants were harvested and levels of IL-12, IL-6 and IL-10 were determined. Dots represent
data from individual tissues, and lines indicate mean values. (B) Graded numbers of hepatic LN (solid symbols) and spleen (open symbols) cDC2 from the same
donors were co-cultured with graded numbers of allogeneic T cells (from one batch) and T-cell proliferation was assessed after 5 days by [3H]-thymidine
incorporation. Dots represent data from individual tissues and lines indicate mean values. (C) Naïve allogeneic CD3+CD45RA+ T cells were co-cultured with cDC2
purified from hepatic LN or spleen from the same donors. After 7 days the T-cells were re-stimulated with PMA and ionomycin for 6 h. For the last 5 h brefeldin A was
added. Representative dot plots of intracellular expression of IFN-γ in CD3+ T cells are shown, and a summary of the results from experiments with cDC2 purified
from tissues of 3 different donors is depicted. Dots represent data from individual tissues and lines indicate mean values.
Liver LN Contain Relatively Low Numbers
of Plasmacytoid Dendritic Cells
Relative PDC numbers within CD45+ MNC of the different
tissues were determined using anti-BDCA2 and anti-BDCA4
antibodies (Figure 4A). Hepatic LN contained on average 0.13%
PDC, which is comparable to the relative numbers of PDC
in spleen (0.14%) and liver (0.19%), but ∼7 times lower
than PDC numbers in inguinal LN (0.95%; Figure 4B). The
maturation status of PDC was assessed by determination of the
expression of HLA-DR, CD40, CD86, and PDL-1. In none of
the examined tissues CD86 expression was detected on PDC,
and PDL-1 expression was very low (data not shown). CD40
and HLA-DR expression on PDC did not differ between the
tissues (Figures 4C,D). In addition, PDC isolated from liver LN
and inguinal LN showed comparable ex vivo allogeneic T-cell
stimulatory capacity (Figure 4E).
Liver LN Contain Relatively Low Numbers
of CD14+DC-SIGN+Macrophages
In addition to the two MDC-subsets and PDC, we detected
CD14+ cells in spleen and liver (5.0 ± 0.5% and 11.3 ±
2.8% of total CD45+MNC, respectively). In contrast, these cells
were rare in both types of LN, but hepatic LN contained
even 2-fold lower relative numbers compared to inguinal LN
(0.23 ± 0.06% and 0.53 ± 0.03% of CD45+MNC, respectively;
Figures 5A,B). CD14+ cells in both types of LN expressed much
higher levels of DC-SIGN compared to those in spleen and
liver (Figures 5C,D). In preliminary experiments in which we
compared MNC isolations from LN or spleen with or without
collagenase treatment, we observed that DC-SIGN expression
was affected by collagenase digestion of the tissue (Figure 5B).
Therefore, the expression levels of DC-SIGN on CD14+ cells
isolated after collagenase digestion depicted in Figure 5D are
probably under-estimations, except for liver cells which were
always obtained as single cells present in liver perfusates and
therefore not treated with collagenase. In all examined tissues
the majority of CD14+ cells expressed CD163 (Figure 5E), but
not CD206 (data not shown), suggesting that these cells represent
macrophages (38, 40). Liver CD14+ cells representmost probably
Kupffer cells, which have been shown to express low levels of DC-
SIGN (41). The majority of CD14+DC-SIGN+CD206− cells in
LN have been shown to represent subcapsular macrophages (42,
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FIGURE 4 | PDC in hepatic and inguinal lymph nodes, spleen and liver. (A) Flowcytometric determination of PDC in MNC isolated from hepatic and inguinal lymph
nodes, spleen, and liver perfusate using anti-BDCA2 and anti-BDCA4 antibodies. Non-hematopoietic cells and dead cells were excluded from the analysis by
exclusion of CD45− cells and 7-AAD+ cells. (B) Percentages of BDCA2+BDCA4+ PDC within MNC in the different tissues. Dots represent data from individual
tissues and lines indicate mean values. (C) Histograms showing HLA-DR and CD40 expression on PDC from the different tissues. Light gray histograms are isotype
control stains. (D) Summary of the expression levels of HLA-DR and CD40 on PDC in hepatic (H) lymph nodes (n = 6) and inguinal lymph nodes (n = 7), spleen (n =
6), and liver (n = 6). Data are depicted as means with SEM. No significant differences were observed (E) Graded numbers of purified hepatic (n = 6) and inguinal LN
PDC (n = 5) were co-cultured with allogeneic T-cells (from one batch) and T-cell proliferation was assessed after 5 days by [3H]-thymidine incorporation. T-cell
proliferation in response to PHA is depicted as positive control condition. Data represent means with SEM. No significant differences were observed.
43), while about one third expressed CD169 in addition to DC-
SIGN (data not shown) and may therefore represent medullary
sinus macrophages (43, 44). No CD14+CD169+ cells were found
in spleen and liver. The activation status of the CD14+ cells
was determined by the expression of HLA DR, CD80 and
CD86. None of CD14+ cells in the examined tissues expressed
CD80. Compared to CD14+ cells in inguinal LN, CD14+ cells
in hepatic LN showed lower expression levels of HLA-DR and
CD86, indicating a less activated status of these cells, although
the presence of different macrophage sub-populations in the two
types of LN cannot be excluded (Figures 5F,G).
Decreased Numbers of cDC Subsets but
Increased Numbers of Macrophages and
PDC in Lymph Nodes of Diseased Livers
Finally, we studied whether inflammatory liver disease affects
numbers of the different APC-subsets in hepatic LN. For this
purpose, we isolated MNC from freshly resected liver LN
collected during liver transplant procedures from explant livers
of patients with primary sclerosing cholangitis or auto-immune
hepatitis, and compared relative numbers of the different APC
subsets within CD45+ MNC with those in liver LN isolated
from healthy livers of multi-organ donors. Interestingly, relative
numbers of cDC1 were decreased, while relative numbers of
macrophages and PDC were increased in hepatic LN of patients
with inflammatory liver disease compared to hepatic LN from
healthy liver (Figures 6A,B).
DISCUSSION
Previous studies have shown that human LN contain two main
cDC subsets which correspond to the two main cDC subsets in
blood: CD141bright cDC1 and CD1c+cDC2 and (14, 38). The
present study shows that the same cDC subsets are present in
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FIGURE 5 | Relative CD14+ cell numbers and their activation status in hepatic and inguinal lymph nodes, spleen, and liver. (A) CD14+ cells were determined within
vital CD45− MNC. Representative dot plots are shown. (B) A summary of the percentages of CD14+ cells within vital CD45− MNC isolated from the different tissues.
Data from individual tissues are depicted as dots and lines indicate mean values on a log-scale. (C) DC-SIGN-expression on CD14+ cells that were isolated from
tissues with collagenase or without collagenase treatment. Tissues were divided into two parts, and after cutting into small pieces, one part was treated with
collagenase and the other part not. After that, single cell suspensions were made from both parts. (D) Summary showing DC-SIGN expression levels on CD14+ cells
from liver lymph nodes (n = 6) and inguinal lymph nodes (n = 7), spleen (n = 6), and liver (n = 6). Except for liver, MNC were isolated from the tissues using
collagenase. Data are depicted as means with SEM. (E) CD163 expression on CD14+ cells in MNC from liver LN, inguinal LN, spleen and liver perfusate. (F)
Histograms showing HLA-DR and CD86 expression on CD14+ cells in the different tissues. Light gray histograms are isotype control stains. (G) Summary of HLA-DR
and CD86 expression levels on CD14+ cells in liver lymph nodes (n = 6), inguinal lymph nodes (n = 7), spleen (n = 6), and liver (n = 6). Data are depicted as means
with SEM.
liver LN. However, cDC2 are present at much lower relative
numbers in hepatic LN compared to skin/muscle-draining
inguinal LN and spleen, while cDC1 are a minor subset in both
hepatic and inguinal LN. Like cDC1, cDC2 can stimulate both
CD4+ and CD8+ T cells (10), but cDC2 can produce IL-12 while
cDC1 cannot (39, 45). Since IL-12 is a main driver of T-helper 1
differentiation and cytotoxic CD8+ T cell responses, the reduced
numbers of cDC2 in hepatic LN may contribute to the relatively
low immunogenicity of the liver environment.
Interestingly, both cDC subsets displayed a more mature
phenotype with higher expression of co-stimulatory molecules
in hepatic LN compared to inguinal LN, iliacal LN, spleen, and
liver. This observation is in line with a previous study showing
that rat liver lymph contains highly mature MDC (46). The
enhanced maturation status of cDC in hepatic LN may be caused
by stimulation by bacterial products, such as endotoxins, that
continuously enter the liver from the intestinal tract via the
portal circulation. Such stimulation may have occurred in the
liver before migration of cDC to the sentinel LN or in the
LN. Nevertheless, cDC2 isolated from hepatic LN showed a
comparable T-cell stimulatory capacity, cytokine production and
capacity to induce IFNγ production in naïve T-cells compared
to those isolated from spleen. We speculate that the enhanced
expression of the co-inhibitory ligand PDL-1 on MDC in
hepatic LN may compensate for the enhanced expression of co-
stimulatory molecules in T-cell stimulation. The equal capacity
of hepatic LN and splenic cDC2 to induce IFNγ-production in
naïve T cells is probably associated with their similar capacity
to produce IL-12. Our current data show that cDC2 in human
liver LN are not functionally compromised, as has been suggested
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FIGURE 6 | (A) Relative numbers of APC subsets in liver lymph nodes of patients with inflammatory liver diseases. Flowcytometric analysis of cDC1 and cDC2 in
single cell suspension of a LN attached to an explanted liver of a PSC patients. Within viable CD45+ cells, CD141hi cDC1 and CD11c+CD1c+ cDC2 were gated.
(B)The percentages of cDC1, cDC2, PDC, and CD14+ cells were determined within CD45+ MNC in hepatic lymph nodes derived from healthy donors (HD; n = 8)
and patients with inflammatory liver disease (ILD; n = 10 for cDC1 and n = 3 for cDC2). Patients with primary sclerosing cholangitis are depicted as squares and
patients with auto-immune hepatitis as triangles. Lines indicate means.
previously for cDC in mouse liver (19, 20, 22). Accordingly,
we have previously shown that cDC2 isolated from human
liver tissue are able to produce pro-inflammatory cytokines and
acquire T-cell stimulatory capacity upon TLR-activation (28).
We expected that liver inflammation would enhance
migration of cDC to the draining LN, and thereby cause
increased numbers of cDC in hepatic LN. Indeed, induction of
inflammation in the skin by local injection of a TLR-9 agonist
and GM-CSF into the scar of resected melanoma resulted in
selectively increased numbers of cDC1 in sentinel lymph nodes
(47). Moreover, inflammatory liver disease is associated with
depletion of cDC1 from human liver, and is was hypothesized
that they might have migrated to hepatic LN due to inflammatory
stimuli (25). In contrast to our expectation, relative numbers
of cDC1 were reduced in LN attached to inflamed livers
compared to those in LN of healthy livers. We hypothesize
that the decreased relative numbers of cDC1 in hepatic LN
in these patients might be caused by activation-induced cell
death or, alternatively, that liver cirrhosis impedes migration
of MDC through lymphatics to the regional LN. It is tempting
to speculate that the paucity of cDC1 in sentinel liver LN
in end-stage liver diseases may lead to a further mitigation
of T-cell responses to liver-derived antigens compared to
healthy livers.
We confirm our previous finding that hepatic LN (48) contain
much lower numbers of PDC than skin/muscle draining inguinal
LN. However, we now show that PDC from both types of LN
do not differ in terms of activation/maturation status and T-
cell stimulatory capacity. Differences in migration route between
MDC and PDC may explain the similar maturation status of
PDC in hepatic and inguinal LN. PDC do not migrate via the
lymph to LN, but migrate from the blood circulation into LN
via the high endothelial venules, and are mainly attracted by
the CCR-7 ligands CCL19 and CCL21 (49, 50). Therefore, they
are probably not exposed to maturation stimuli present in the
liver environment, like cDC. PDC are important in anti-viral
defense by production of IFN-α, amongst others against HCV
(51, 52), but can also present antigens to T-cells. They are able
to prime productive effector T-cell responses (9, 16), but can also
induce differentiation of CD4+ as well as CD8+ Treg (17, 18).
The circumstances in which the balance tips toward activation
of effector T cells or Treg are not well-understood, and probably
depend on the micro-environmental conditions in the tissue
in which they reside. In addition to their capacity to directly
activate T cells, PDC interact with cDC to enhance their T-cell
stimulatory capacity (53, 54). Together, it is difficult to speculate
on the immunological consequences of the low numbers of
PDC in hepatic LN under steady state conditions. However,
in contrast to cDC, numbers of PDC are increased in sentinel
LN of inflamed livers with cholestatic or auto-immune diseases.
Apparently, hepatic LN can “normalize” their PDC content
during liver inflammation. We speculate that liver inflammation
leads to increased production of CCL19 and CCL21 and/or other
chemo-attractants in hepatic LN, that induce migration of PDC
into LN.
In addition to cDC and PDC, also macrophages are able to
present antigens to T cells although less efficiently (55). Liver
LN were found to contain 2-fold lower numbers of CD14+
macrophages than in skin/muscle draining inguinal LN. Based
on their immunophenotype, the majority of these cells are
probably subcapsular macrophages, whose main function is to
capture lymph-born viral particles and present them to B-cells
(56). However, they are also able to cross-present lymph-derived
antigens to CD8+ T cells (57, 58), and promote activation of NK-
cells, NKT-cells, PDC and γδ-T-cells, possibly via production of
type I IFN, IL12 and IL18 (59). In contrast to cDC, CD14+ cells
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in hepatic LN showed a reduced maturation status compared to
their counterparts in inguinal LN. The origin of the macrophages
in liver LN is currently unknown. One possibility is that (a subset
of) Kupffer cells migrate via lymph to hepatic LN, but in rat it
has been shown that liver lymph does not contain Kupffer cells
(30). Since macrophages are also present in inguinal LN, even in
higher numbers, we favor the hypothesis that these macrophages
derived from circulating monocytes. This hypothesis would also
explain the relatively low activation status of these cells in liver
LN, because they have, like PDC, not been exposed to endotoxins
present in the liver. It can also explain the increase in CD14+
cells in lymph nodes during inflammatory conditions, since
monocyte chemoattractant protein (MCP)-1 increases at the
luminal surface of high endothelial venules during inflammation,
which enhances the migration of CD14+ cells into LN (60).
The strength of this study is that we are the first to
comprehensively characterize APC subsets in human liver lymph
nodes. Limitations of our study are that: (1) We could not
study the functional properties of cDC1 in liver LN, because
it was impossible to isolate sufficient numbers of this rare
subset; (2) Since the numbers of fluorochrome channels on our
flowcytometer were limited to 8, we could not include CD11c
in all phenotypic analysis of cDC2. However, main findings on
the phenotypes of cDC2 were confirmed in measurements that
included CD11c in the gating strategy.
In summary, we observed that in steady state conditions
human liver LN contain relatively low numbers of cDC2,
PDC, and subcapsular macrophages. Whereas, numbers of
cDC1 further decrease during liver inflammation and cirrhosis,
numbers of PDC and subcapsular macrophages increase,
suggesting important contributions of these APC cell subsets to
liver immunity. Functional studies are required to reveal whether
these APC cell subsets do play a role in regulating liver immunity.
Importantly, we found that cDC2 in hepatic LN are not
dysfunctional. The paucity of both main subsets of cDC subsets
in liver LN, both during steady state conditions and during liver
inflammation, may contribute to the immunologically tolerant
liver environment.
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